SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2023

SEGMENT REPORTING

Schedule of financial information by reportable segments

	Three Months Ended March 31,
(in thousands)	2023		2022
Net Revenues
Generics, Established Brands, and Other	$	90,456	$	63,185
Rare Disease		16,330		1,292
Total net revenues	$	106,786	$	64,477
Segment earnings (loss) before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to income (loss) before income taxes
Generics, Established Brands, and Other	$	38,828	$	14,531
Rare Disease		(1,251)		(10,448)
Depreciation and amortization		(14,700)		(14,557)
Corporate and other unallocated expenses(1)		(12,982)		(8,721)
Total operating income (loss)		9,895		(19,195)
Interest expense, net		(7,696)		(6,613)
Other expense, net		(34)		(89)
Income (loss) before (provision) benefit for income taxes	$	2,165	$	(25,897)

(1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations.

Schedule of revenue by geographic operations

(in thousands)	Three Months Ended March 31,
Location of Operations	2023		2022
United States	$	106,221	$	63,760
Canada		565		717
Total Revenue	$	106,786	$	64,477

Schedule of property, plant and equipment, net by geographic location

(in thousands)	March 31, 2023		December 31, 2022
United States	$	42,024	$	40,343
Canada(1)		—		1,856
India		1,251		1,047
Total property and equipment, net	$	43,275	$	43,246

(1) Amounts as of March 31, 2023 exclude the land and building at our Canada facility, which are classified as held for sale as of March 31, 2023. These assets have a carrying value of $8.0 million.